Ambrx Biopharma (NYSE:AMAM) Vs. Fennec Pharmaceuticals (NASDAQ:FENC) Head-To-Head Survey
Ambrx Biopharma (NYSE:AMAM) Vs. Fennec Pharmaceuticals (NASDAQ:FENC) Head-To-Head Survey
Ambrx Biopharma (NYSE:AMAM – Get Rating) and Fennec Pharmaceuticals (NASDAQ:FENC – Get Rating) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, profitability, analyst recommendations, earnings, dividends and risk.
安博士生物医药(NYSE：AMAM-GET Rating)和芬内克制药(Fennec PharmPharmticals)(纳斯达克：FENC-GET Rating)都是小盘医疗公司，但哪只股票更优越？我们将根据这两家公司的估值、机构所有权、盈利能力、分析师建议、收益、股息和风险等方面的实力进行比较。
Volatility and Risk
波动性和风险
Ambrx Biopharma has a beta of -2.17, indicating that its share price is 317% less volatile than the S&P 500. Comparatively, Fennec Pharmaceuticals has a beta of 0.03, indicating that its share price is 97% less volatile than the S&P 500.
Ambrx Biophma的贝塔系数为-2.17，表明其股价的波动性比标准普尔500指数低317%。相比之下，Fennec PharmPharmticals的贝塔系数为0.03，表明其股价的波动性比标准普尔500指数低97%。
Insider and Institutional Ownership
内部人与机构持股
43.1% of Ambrx Biopharma shares are owned by institutional investors. Comparatively, 43.3% of Fennec Pharmaceuticals shares are owned by institutional investors. 5.1% of Ambrx Biopharma shares are owned by company insiders. Comparatively, 9.4% of Fennec Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Ambrx Biophma 43.1%的股份由机构投资者持有。相比之下，Fennec PharmPharmticals 43.3%的股份由机构投资者持有。Ambrx Biophma 5.1%的股份由公司内部人士持有。相比之下，Fennec PharmPharmticals 9.4%的股份由公司内部人士持有。强大的机构持股表明，大型基金管理公司、对冲基金和捐赠基金相信，一家公司的长期表现将好于大盘。
Profitability
盈利能力
| Net Margins | Return on Equity | Return on Assets | |
| Ambrx Biopharma | N/A | N/A | N/A |
| Fennec Pharmaceuticals | N/A | -214.78% | -97.25% |
| 净利润率 | 股本回报率 | 资产回报率 | |
| Ambrx Biopma | 不适用 | 不适用 | 不适用 |
| 芬内克制药公司 | 不适用 | -214.78% | -97.25% |
Analyst Recommendations
分析师建议
This is a summary of current ratings and price targets for Ambrx Biopharma and Fennec Pharmaceuticals, as provided by MarketBeat.
这是MarketBeat提供的Ambrx Biophma和Fennec PharmPharmticals的当前评级和目标价摘要。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Ambrx Biopharma | 0 | 1 | 1 | 0 | 2.50 |
| Fennec Pharmaceuticals | 0 | 0 | 5 | 0 | 3.00 |
| 销售评级 | 保持评级 | 购买评级 | 强劲的买入评级 | 评级分数 | |
| Ambrx Biopma | 0 | 1 | 1 | 0 | 2.50 |
| 芬内克制药公司 | 0 | 0 | 5 | 0 | 3.00 |
Ambrx Biopharma presently has a consensus target price of $4.00, indicating a potential upside of 108.33%. Fennec Pharmaceuticals has a consensus target price of $14.83, indicating a potential upside of 49.38%. Given Ambrx Biopharma's higher probable upside, equities research analysts plainly believe Ambrx Biopharma is more favorable than Fennec Pharmaceuticals.
Ambrx Biophma目前的共识目标价为4美元，表明潜在涨幅为108.33%。Fennec PharmPharmticals的共识目标价为14.83美元，表明潜在上行49.38%。考虑到Ambrx Biophma更有可能上行，股票研究分析师显然认为Ambrx Biophma比Fennec PharmPharmticals更有利。
Earnings & Valuation
收益与估值
This table compares Ambrx Biopharma and Fennec Pharmaceuticals' gross revenue, earnings per share and valuation.
此表比较了Ambrx Biophma和Fennec制药公司的毛收入、每股收益和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Ambrx Biopharma | $7.45 million | 9.95 | -$68.08 million | N/A | N/A |
| Fennec Pharmaceuticals | $170,000.00 | 1,539.79 | -$17.35 million | ($0.82) | -12.11 |
| 总收入 | 价格/销售额比 | 净收入 | 每股收益 | 市盈率 | |
| Ambrx Biopma | 745万美元 | 9.95 | -6,808万元 | 不适用 | 不适用 |
| 芬内克制药公司 | $170,000.00 | 1,539.79 | -1,735万美元 | ($0.82) | -12.11 |
Fennec Pharmaceuticals has lower revenue, but higher earnings than Ambrx Biopharma.
Fennec PharmPharmticals的收入低于Ambrx Biophma，但收益高于Ambrx Biophma。
Summary
摘要
Fennec Pharmaceuticals beats Ambrx Biopharma on 7 of the 11 factors compared between the two stocks.
Fennec PharmPharmticals在两只股票比较的11个因素中有7个击败了Ambrx Biophma。
About Ambrx Biopharma
关于Ambrx Biophma
(Get Rating)
(获取评级)
Ambrx Biopharma Inc., a clinical-stage biologics company, discovers and develops engineered precision biologics using its proprietary expanded genetic code technology platform. Its lead product candidate is ARX788, an anti-HER2 antibody-drug conjugate (ADC), which is investigated in various clinical trials for the treatment of breast cancer, gastric/gastroesophageal junction cancer, and other solid tumors, including ongoing Phase 2/3 clinical trials for the treatment of HER2-positive metastatic breast cancer and gastric cancer. The company is also developing two earlier-stage product candidates, including ARX517, an anti-PSMA ADC, which is in a Phase 1 clinical trial for the treatment of prostate cancer and other solid tumors; and ARX305, an anti-CD70 ADC in investigational new drug-enabling studies for the treatment of renal cell carcinoma and other cancers. In addition, it is developing other multiple product candidates targeting immuno-oncology applications, which include ARX822, a fab-small molecule bispecific that is in preclinical development for cancers; and ARX102, an immuno-oncology IL-2 pathway agonist to stimulate the patient's own immune system by targeting the ß and gamma receptors on the cytotoxic T cell. Ambrx Biopharma Inc. has collaborations with Bristol Myers Squibb Company; AbbVie Inc.; BeiGene; Sino Biopharmaceutical Co., Ltd.; NovoCodex; and Elanco Animal Health. The company was incorporated in 2003 and is headquartered in La Jolla, California.
Ambrx Biophma Inc.是一家临床阶段的生物制品公司，利用其专有的扩展遗传密码技术平台发现和开发工程精密生物制品。它的主要候选产品是ARX788，这是一种抗HER2抗体-药物结合物(ADC)，用于治疗乳腺癌、胃/胃食道交界处癌症和其他实体肿瘤的各种临床试验，包括正在进行的治疗HER2阳性转移性乳腺癌和胃癌的2/3期临床试验。该公司还在开发两种早期候选产品，包括ARX517和ARX305。ARX517是一种抗PSMA ADC，处于治疗前列腺癌和其他实体肿瘤的第一阶段临床试验；ARX305是一种抗CD70 ADC，正在研究治疗肾癌和其他癌症的新药。此外，该公司还在开发针对免疫肿瘤学应用的其他多种候选产品，其中包括ARX822，一种用于癌症临床前开发的Fab-小分子双特异性药物；以及ARX102，一种免疫肿瘤学IL-2途径激动剂，通过靶向细胞毒性T细胞上的吗和伽马受体来刺激患者自身的免疫系统。Ambrx Biophma Inc.与百时美施贵宝公司、艾伯维公司、百济神州、中国生物制药有限公司、NovoCodex和Elanco Animal Health有合作关系。该公司成立于2003年，总部设在加利福尼亚州拉荷亚。
About Fennec Pharmaceuticals
关于Fennec制药公司
(Get Rating)
(获取评级)
Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.
生物制药公司Fennec PharmPharmticals Inc.开发用于美国癌症治疗的候选产品。它的主要候选产品是硫代硫酸钠，已经完成了预防顺铂引起的儿童听力损失或耳毒性的第三阶段临床试验。该公司前身为Adherex Technologies Inc.，2014年9月更名为Fennec PharmPharmticals Inc.。Fennec制药公司成立于1996年，总部设在北卡罗来纳州的研究三角公园。
Receive News & Ratings for Ambrx Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ambrx Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
接受《Ambrx Biophma Daily》的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Ambrx Biophma和相关公司的最新新闻和分析师评级的每日简要摘要。